With falling R&D productivity, continued healthcare cost containment and the threat of generic competition, only those companies who combine internal efforts with effective licensing strategies will remain competitive over the next five-to-ten years.
Pharmaceutical Licensing Strategies: Best practices in deal-making, valuations and strategic management is the only report available that combines up-to-date analysis of recent deal trends and best practices with a detailed guide to the licensing and deal-making process, ensuring that you are able to optimize your strategic licensing activities.
Top 5 reasons to read this report
- Understand how the dynamics of licensing deals have changed in the last 5 years, including the increasing complexity of multiple development compound deals and the shifting balance of power between the licensee and licensor.
- Gain access to a survey of over 140 licensing experts ensuring you implement optimal licensing processes and commit adequate resources to support deal-making.
- Profile the leading deals and deal-makers over the past 5 years, identify the key factors of success and apply the report’s actionable recommendations.
- Implement effective alliance management processes to ensure the success of your current licensing deals and become the partner of choice for the future.
- Apply the independent licensing valuation model presented in this report in order to begin more collaborative licensing negotiations and maximize the value of your deal for both parties.
Key findings of this report
- The larger biotech companies now have the resources and the capabilities to develop lead drugs to later stages of development before seeking a pharmaceutical partner, and are now able to compete with pharmaceutical companies for the best in-licensing deals from emerging biotech.
- While the value of licensing deals has risen markedly in the last 5 years, the volume of deals among the top companies has plateaued. Companies are increasingly seeking out long-term, multi-product, multi-indication collaborations rather than one-off transactional deals.
- Using independent and unbiased model inputs in the licensing valuation process limits areas of subjective disagreement, and allows deal terms to be maximized for both parties.
- A successful deal cannot only be judged by deal terms and revenues gained from the eventual product; the quality of the relationship between licensing partners is also equally important.
For more information, please call 877/437-4276 or e-mail epharm@hcpro.com
Save money when you purchase multiple copies! Ask your customer service representative about money-saving
discounts and bulk orders. Call toll free 800-650-6787 or e-mail
customerservice@hcpro.com.
